Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04370483 · ClinicalTrials.gov registry record · Early Phase 1
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma
A Early Phase 1 study of Smoldering Plasma Cell Myeloma, sponsored by City of Hope Medical Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT04370483 is a Early Phase 1 study of Smoldering Plasma Cell Myeloma that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 1 participants, below the 139-participant average among 9 other Smoldering Plasma Cell Myeloma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04370483, a Early Phase 1 study of Smoldering Plasma Cell Myeloma, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot trial studies how well leflunomide works for the treatment of patients with high-risk smoldering plasma cell myeloma, for the delay of disease progression. Anti-inflammatory drugs, such as leflunomide lower the body's immune response and are used with other drugs in the treatment of some types of cancer. The information learned from this study will help researchers to learn more about the anti-myeloma activity of leflunomide, and whether it may delay the onset of symptomatic multiple myeloma in patients with high-risk smoldering multiple myeloma.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- DRUG Leflunomide
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-10-08 |
| Est. Completion | 2026-11-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04370483
The ClinicalTrials.gov registry entry for NCT04370483 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 139-participant average among 9 other Smoldering Plasma Cell Myeloma trials with a reported enrollment target (99% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smoldering Plasma Cell Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Quality-of-Life Assessment is the first listed.
NCT04370483 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04370483 about?
NCT04370483 is a clinical study titled "Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma". This pilot trial studies how well leflunomide works for the treatment of patients with high-risk smoldering plasma cell myeloma, for the delay of disease progression. Anti-inflammatory drugs, such as leflunomide lower the body's immune response and are used with other drugs in the treatment of some ...
What is the current status of trial NCT04370483?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2020-10-08. Estimated completion is 2026-11-10.
What conditions does trial NCT04370483 study?
This clinical trial studies the following conditions: Smoldering Plasma Cell Myeloma.
What interventions are being tested in trial NCT04370483?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Leflunomide (DRUG).
Who is sponsoring clinical trial NCT04370483?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04370483 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoldering Plasma Cell Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma
ACTIVE NOT RECRUITING · Early Phase 1
-
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
RECRUITING
-
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
RECRUITING · Phase 3
-
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
RECRUITING · Phase 2
-
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
RECRUITING · NA
-
Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.